Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

Joan M. Bathon, Roy M. Fleischmann, Désirée M. Van Der Heijde, John R. Tesser, Paul M. Peloso, Yun Chon, Barbara White

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate safety and efficacy of etanercept treatment in elderly (age ≥ 65 yrs) and younger adult subjects (age <65 yrs) with rheumatoid arthritis (RA). Methods. Subset analyses were used to describe the safety and efficacy of etanercept in elderly and younger subjects treated for early and disease modifying antirheumatic drug-resistant or late-stage RA (ERA and LRA) in one of 4 randomized controlled clinical studies (N = 1353) or 2 longterm extensions (N = 1049). Results. Rates of serious adverse events tended to be higher in elderly than younger subjects; however, rates of safety events observed in elderly etanercept-treated subjects did not exceed rates in elderly placebo or methotrexate (MTX)-treated subjects. With regard to efficacy measures [American College of Rheumatology 20% response (ACR20), ACR50, and ACR70], elderly subjects tended to have somewhat less robust responses to treatment than younger subjects. However, for both age groups, treatment with etanercept resulted in improved efficacy and function compared with control treatment, and combination therapy with etanercept plus MTX resulted in greater efficacy than either etanercept or MTX used alone. Efficacy responses of elderly subjects were sustained for up to 6 years. Radiographic progression (measured using modified Sharp Score) after one year of treatment was lower in subjects treated with both etanercept and MTX compared with subjects treated with either agent used alone, and this pattern was similar in both age groups. Conclusion. Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalJournal of Rheumatology
Volume33
Issue number2
StatePublished - Feb 2006

Fingerprint

Rheumatoid Arthritis
Safety
Methotrexate
Age Groups
Therapeutics
Antirheumatic Agents
Etanercept
Young Adult
Placebos

Keywords

  • Elderly
  • Etanercept
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Bathon, J. M., Fleischmann, R. M., Van Der Heijde, D. M., Tesser, J. R., Peloso, P. M., Chon, Y., & White, B. (2006). Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Journal of Rheumatology, 33(2), 234-243.

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. / Bathon, Joan M.; Fleischmann, Roy M.; Van Der Heijde, Désirée M.; Tesser, John R.; Peloso, Paul M.; Chon, Yun; White, Barbara.

In: Journal of Rheumatology, Vol. 33, No. 2, 02.2006, p. 234-243.

Research output: Contribution to journalArticle

Bathon, JM, Fleischmann, RM, Van Der Heijde, DM, Tesser, JR, Peloso, PM, Chon, Y & White, B 2006, 'Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis', Journal of Rheumatology, vol. 33, no. 2, pp. 234-243.
Bathon JM, Fleischmann RM, Van Der Heijde DM, Tesser JR, Peloso PM, Chon Y et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Journal of Rheumatology. 2006 Feb;33(2):234-243.
Bathon, Joan M. ; Fleischmann, Roy M. ; Van Der Heijde, Désirée M. ; Tesser, John R. ; Peloso, Paul M. ; Chon, Yun ; White, Barbara. / Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. In: Journal of Rheumatology. 2006 ; Vol. 33, No. 2. pp. 234-243.
@article{6a437dd29dc54bdbb8c10869449aed7e,
title = "Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis",
abstract = "Objective. To evaluate safety and efficacy of etanercept treatment in elderly (age ≥ 65 yrs) and younger adult subjects (age <65 yrs) with rheumatoid arthritis (RA). Methods. Subset analyses were used to describe the safety and efficacy of etanercept in elderly and younger subjects treated for early and disease modifying antirheumatic drug-resistant or late-stage RA (ERA and LRA) in one of 4 randomized controlled clinical studies (N = 1353) or 2 longterm extensions (N = 1049). Results. Rates of serious adverse events tended to be higher in elderly than younger subjects; however, rates of safety events observed in elderly etanercept-treated subjects did not exceed rates in elderly placebo or methotrexate (MTX)-treated subjects. With regard to efficacy measures [American College of Rheumatology 20{\%} response (ACR20), ACR50, and ACR70], elderly subjects tended to have somewhat less robust responses to treatment than younger subjects. However, for both age groups, treatment with etanercept resulted in improved efficacy and function compared with control treatment, and combination therapy with etanercept plus MTX resulted in greater efficacy than either etanercept or MTX used alone. Efficacy responses of elderly subjects were sustained for up to 6 years. Radiographic progression (measured using modified Sharp Score) after one year of treatment was lower in subjects treated with both etanercept and MTX compared with subjects treated with either agent used alone, and this pattern was similar in both age groups. Conclusion. Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.",
keywords = "Elderly, Etanercept, Rheumatoid arthritis",
author = "Bathon, {Joan M.} and Fleischmann, {Roy M.} and {Van Der Heijde}, {D{\'e}sir{\'e}e M.} and Tesser, {John R.} and Peloso, {Paul M.} and Yun Chon and Barbara White",
year = "2006",
month = "2",
language = "English (US)",
volume = "33",
pages = "234--243",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

AU - Bathon, Joan M.

AU - Fleischmann, Roy M.

AU - Van Der Heijde, Désirée M.

AU - Tesser, John R.

AU - Peloso, Paul M.

AU - Chon, Yun

AU - White, Barbara

PY - 2006/2

Y1 - 2006/2

N2 - Objective. To evaluate safety and efficacy of etanercept treatment in elderly (age ≥ 65 yrs) and younger adult subjects (age <65 yrs) with rheumatoid arthritis (RA). Methods. Subset analyses were used to describe the safety and efficacy of etanercept in elderly and younger subjects treated for early and disease modifying antirheumatic drug-resistant or late-stage RA (ERA and LRA) in one of 4 randomized controlled clinical studies (N = 1353) or 2 longterm extensions (N = 1049). Results. Rates of serious adverse events tended to be higher in elderly than younger subjects; however, rates of safety events observed in elderly etanercept-treated subjects did not exceed rates in elderly placebo or methotrexate (MTX)-treated subjects. With regard to efficacy measures [American College of Rheumatology 20% response (ACR20), ACR50, and ACR70], elderly subjects tended to have somewhat less robust responses to treatment than younger subjects. However, for both age groups, treatment with etanercept resulted in improved efficacy and function compared with control treatment, and combination therapy with etanercept plus MTX resulted in greater efficacy than either etanercept or MTX used alone. Efficacy responses of elderly subjects were sustained for up to 6 years. Radiographic progression (measured using modified Sharp Score) after one year of treatment was lower in subjects treated with both etanercept and MTX compared with subjects treated with either agent used alone, and this pattern was similar in both age groups. Conclusion. Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.

AB - Objective. To evaluate safety and efficacy of etanercept treatment in elderly (age ≥ 65 yrs) and younger adult subjects (age <65 yrs) with rheumatoid arthritis (RA). Methods. Subset analyses were used to describe the safety and efficacy of etanercept in elderly and younger subjects treated for early and disease modifying antirheumatic drug-resistant or late-stage RA (ERA and LRA) in one of 4 randomized controlled clinical studies (N = 1353) or 2 longterm extensions (N = 1049). Results. Rates of serious adverse events tended to be higher in elderly than younger subjects; however, rates of safety events observed in elderly etanercept-treated subjects did not exceed rates in elderly placebo or methotrexate (MTX)-treated subjects. With regard to efficacy measures [American College of Rheumatology 20% response (ACR20), ACR50, and ACR70], elderly subjects tended to have somewhat less robust responses to treatment than younger subjects. However, for both age groups, treatment with etanercept resulted in improved efficacy and function compared with control treatment, and combination therapy with etanercept plus MTX resulted in greater efficacy than either etanercept or MTX used alone. Efficacy responses of elderly subjects were sustained for up to 6 years. Radiographic progression (measured using modified Sharp Score) after one year of treatment was lower in subjects treated with both etanercept and MTX compared with subjects treated with either agent used alone, and this pattern was similar in both age groups. Conclusion. Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.

KW - Elderly

KW - Etanercept

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=32144446399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144446399&partnerID=8YFLogxK

M3 - Article

C2 - 16465653

AN - SCOPUS:32144446399

VL - 33

SP - 234

EP - 243

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -